Gefitinib ('Iressa', ZD1839) in heavily pretreated non-small-cell lung cancer patients: a case series report from the 'Iressa' Expanded Access Programme

被引：0
|
作者：
Gridelli, C [1 ]
Rossi, A [1 ]
Maione, P [1 ]
Musto, L [1 ]
Del Gaizo, F [1 ]
Airoma, G [1 ]
机构：
[1] SG Moscati Hosp, Avellino, Italy
来源：
BRITISH JOURNAL OF CANCER | 2003年 / 89卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S29 / S29
页数：1
相关论文
共 50 条
  • [41] Gefitinib ('Iressa', ZD1839) as third-line therapy for a patient with symptomatic brain metastases from non-small-cell lung cancer
    Azémar, M
    Stoll, C
    Unger, C
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S25 - S25
  • [42] Activity of a specific inhibitor, gefitinib (Iressa™, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer
    Santoro, A
    Cavina, R
    Latteri, F
    Zucali, PA
    Ginanni, V
    Campagnoli, E
    Ferrari, B
    Morenghi, E
    Pedicini, V
    Roncalli, A
    Alloisio, M
    Ravasi, G
    Parral, HJS
    [J]. ANNALS OF ONCOLOGY, 2004, 15 (01) : 33 - 37
  • [43] Quality-of-life benefits for a patient with non-small-cell lung cancer and brain metastases taking gefitinib ('Iressa', ZD1839)
    van Zandwijk, N
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S34 - S34
  • [44] Clinically meaningful response case to the EGFR tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in non small cell lung cancer
    Gelibter, A
    Ceribelli, A
    Milella, M
    Mottolese, M
    Vocaturo, A
    Cognetti, F
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2003, 22 (03) : 481 - 485
  • [45] ZD1839 (Iressa™):: For more than just non-small cell lung cancer
    Ranson, M
    [J]. ONCOLOGIST, 2002, 7 : 16 - 24
  • [46] Cell growth after withdrawal of gefitinib ('Iressa', ZD1839) in human lung cancer cells
    Satoh, H
    Ishikawa, H
    Nakayama, M
    Fujiwara, M
    Ohtsuka, M
    Sekizawa, K
    [J]. ONCOLOGY REPORTS, 2004, 12 (03) : 615 - 619
  • [47] Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer
    H S Parra
    R Cavina
    F Latteri
    P A Zucali
    E Campagnoli
    E Morenghi
    G C Grimaldi
    M Roncalli
    A Santoro
    [J]. British Journal of Cancer, 2004, 91 : 208 - 212
  • [48] Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer
    Parra, HS
    Cavina, R
    Latteri, F
    Zucali, PA
    Campagnoli, E
    Morenghi, E
    Grimaldi, GC
    Roncalli, M
    Santoro, A
    [J]. BRITISH JOURNAL OF CANCER, 2004, 91 (02) : 208 - 212
  • [49] Getitinib (ZD1839, Iressa®) in non-small-cell lung cancer:: a review of clinical trials from a daily practice perspective
    Barlési, F
    Tchouhadjian, C
    Doddoli, C
    Villani, P
    Greillier, L
    Kleisbauer, JP
    Thomas, P
    Astoul, P
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2005, 19 (03) : 385 - 393
  • [50] Complete response of brain metastases from lung adenocarcinoma with gefitinib ('Iressa', ZD1839)
    Maione, P
    Musto, L
    Rossi, A
    Nicolella, D
    Lombardi, C
    Gridelli, C
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S30 - S30
12345